Pseudomonas Aeruginosa Serotyping Kit
Technology owned by University of Guelph. Erfa Biotech operates under an agreement with Société en Commandite Biotech CardioVision and Rougier Biotech Ltée.
Mouse monoclonal antibodies against serotype strains of Pseudomonas Aeruginosa for serotyping and detection of Psedomonas Aeruginosa bacteremia
Erfa Biotech offers the most complete set of monoclonal antibodies against 17 standard (IATS) O serotype strains of Pseudomonas Aeruginosa. Antibodies are very well characterized with respect to specificity, isotypes and strength.
These antibodies represent a bank of invaluable immunological reagents which may have application in serotyping, epitope mapping, lipopolysaccharide structural determination and studies of protection against Pseudomonas Aeruginosa.
One monoclonal antibody specific for each serogroup was chosen to form a kit of antibodies. The format of the test is by the bacterial slide agglutination test in which a small loopful of bacteria from an agar culture can be mixed with a small drop (10 µl) of antibody solution on a microscope slide.
Positive agglutination can easily be seen within 10 second.
The advantage of such a test is that technologists from any clinical laboratory will be able to perform the test, and no special training is required.
To kit has been tested in several clinical centers, which include: the British Columbia's Children Hospital in Vancouver, the Cystic Fibrosis Centre of the States Hospital of Denmark in Copenhagen, the Pediatric Group in the University of Alberta Hospital in Edmonton, the University of Louisville, and the Montreal General Hospital.
Thus far, we have tested the antibodies on more than 600 clinical isolates of Pseudomonas Aeruginosa, and the results have shown good agreement on all strains typable with the commercially available Difco Pseudomonas typing sera. Additionally, the occurence of nontypable and polytypable strains was drastically decreased when the monoclonal antibodies were used.
Cross-reactions that lead to polytypability and nontypability are common problems when the Difco sera are used, and such cross-reactions are not observed with the use of our monoclonal antibody kit.
As for diagnostic purposes, the antibodies were raised specifically against lipopolysaccharides of Pseudomonas Aeruginosa, thus they can easily be mixed as a coctail of the 17 antibodies.
Pseudomonas Aeruginosa is an important bacterial pathogen of nosocomial (hospital derived) infections, and it can also cause life threatening diseases in patients with cancer, burn wounds, cystic fibrosis and in those that have received immunosuppresive therapy.
Thus, the classification of Pseudomonas Aeruginosa isolates is an important and routine task in hospitals.
Currently, the most common method used in most hospitals is serotyping, and a set of typing antisera (polyclonal antibodies from rabbits) which is commercially available from Difco Laboratory.
The set of antibodies we have produced is an natural candidate to replace the Difco sera which has the usual batch to batch variability and the cross-reaction problems mentioned previously.
| Assays | SKU # | Format |
| 100 | 76619 | kit |
| 50 | 76719 | kit |